Hemorrhage of a pancreatic metastasis from lung adenocarcinoma after osimertinib therapy.
作者信息
Hayasaka Kazuki, Shiono Satoshi, Yanagawa Naoki, Yarimizu Kei, Suzuki Katsuyuki, Endoh Makoto
机构信息
Department of Thoracic Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.
Department of Pathology, Yamagata Prefectural Central Hospital, Yamagata, Japan.
出版信息
J Thorac Dis. 2018 Sep;10(9):E686-E689. doi: 10.21037/jtd.2018.08.108.
Abstract
摘要
相似文献
1
Hemorrhage of a pancreatic metastasis from lung adenocarcinoma after osimertinib therapy.奥希替尼治疗后肺腺癌胰腺转移灶出血
J Thorac Dis. 2018 Sep;10(9):E686-E689. doi: 10.21037/jtd.2018.08.108.
2
Analysis of lung adenocarcinoma with bone metastasis: a case report.肺腺癌伴骨转移的分析：一例报告
Transl Lung Cancer Res. 2020 Apr;9(2):389-392. doi: 10.21037/tlcr.2020.03.11.
3
Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report.表皮生长因子受体T790M突变的肺腺癌、体能状态较差患者对奥希替尼的显著颅内反应：一例报告
Mol Clin Oncol. 2017 Apr;6(4):525-528. doi: 10.3892/mco.2017.1181. Epub 2017 Mar 3.
4
A case of osimertinib-resistant lung adenocarcinoma responded effectively to alternating therapy.一例奥希替尼耐药的肺腺癌对交替疗法有效反应。
Ann Transl Med. 2018 Dec;6(23):464. doi: 10.21037/atm.2018.11.25.
5
Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and -C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report.奥希替尼、贝伐单抗和布加替尼联合治疗携带L858R、T790M和-C797S三重EGFR突变的肺腺癌：一例报告
Onco Targets Ther. 2018 Sep 6;11:5545-5550. doi: 10.2147/OTT.S170358. eCollection 2018.
6
Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report.一名肺腺癌患者在奥希替尼诱发急性肺栓塞后用奥希替尼成功进行再治疗：病例报告
Respir Med Case Rep. 2016 Nov 15;20:25-27. doi: 10.1016/j.rmcr.2016.11.009. eCollection 2017.
7
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma.奥希替尼用于治疗表皮生长因子受体第20外显子插入阳性肺腺癌。
EXCLI J. 2019 Oct 7;18:893-898. doi: 10.17179/excli2019-1786. eCollection 2019.
8
Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma.一名肺腺癌患者在奥希替尼诱发肺炎后成功再次使用奥希替尼治疗。
Respir Med Case Rep. 2017 Dec 11;23:68-70. doi: 10.1016/j.rmcr.2017.12.005. eCollection 2018.
9
L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib.在一名对奥希替尼获得性耐药的肺腺癌患者中，出现了L718Q突变且无T790M突变。
Ann Transl Med. 2019 May;7(9):207. doi: 10.21037/atm.2019.04.37.
10
Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib.肺癌治疗的新出现风险概况：奥希替尼所致弥漫性肺泡出血
Case Rep Oncol Med. 2019 Jul 30;2019:6185943. doi: 10.1155/2019/6185943. eCollection 2019.
引用本文的文献
1
Carcinomatous hemorrhagic-calcific metastatic encephalopathy following Osimertinib therapy.
Acta Neurol Belg. 2024 Feb;124(1):291-293. doi: 10.1007/s13760-023-02286-y. Epub 2023 May 17.
2
Intestinal Haemorrhage and Colitis Induced by Treatment With Osimertinib for Non-Small-Cell Lung Carcinoma: A Case Report.奥希替尼治疗非小细胞肺癌所致肠道出血和结肠炎：一例报告
Front Pharmacol. 2022 Apr 5;13:854277. doi: 10.3389/fphar.2022.854277. eCollection 2022.
3
Heterochronous Metastases of Lung Adenocarcinoma to Pancreas and Liver: A Case Report from Pathological Perspectives.肺腺癌异时性转移至胰腺和肝脏：一例病理学视角的病例报告
Onco Targets Ther. 2021 Jul 22;14:4269-4273. doi: 10.2147/OTT.S314385. eCollection 2021.
本文引用的文献
1
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
2
A method of high-throughput functional evaluation of gene variants of unknown significance in cancer.高通量功能评估癌症中未知意义基因变异的方法。
Sci Transl Med. 2017 Nov 15;9(416). doi: 10.1126/scitranslmed.aan6566.
3
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.奥希替尼或铂类培美曲塞用于治疗表皮生长因子受体T790M阳性肺癌
N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.
4
Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.复合表皮生长因子受体（EGFR）突变常与可靶向治疗基因的共突变同时出现，并与肺腺癌的不良临床预后相关。
Cancer Biol Ther. 2016;17(3):237-45. doi: 10.1080/15384047.2016.1139235. Epub 2016 Jan 19.
5
Gastrointestinal bleeding due to pancreatic metastasis of non-small cell lung cancer: A report of two cases and a literature review.非小细胞肺癌胰腺转移导致的胃肠道出血：两例报告及文献复习
Oncol Lett. 2015 May;9(5):2041-2045. doi: 10.3892/ol.2015.3035. Epub 2015 Mar 12.
6
Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation.罕见的表皮生长因子受体（EGFR）第21外显子L858R复合突变与单突变的比较
Onco Targets Ther. 2015 Apr 21;8:905-10. doi: 10.2147/OTT.S78984. eCollection 2015.
7
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.阿法替尼治疗表皮生长因子受体抑制剂耐药的非小细胞肺癌
N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.
8
Diffuse alveolar hemorrhage after erlotinib combined with concurrent chemoradiotherapy in a patient with esophageal carcinoma.一名食管癌患者在接受厄洛替尼联合同步放化疗后发生弥漫性肺泡出血。
Int J Clin Exp Med. 2014 Nov 15;7(11):4492-7. eCollection 2014.
9
Erlotinib and gefitinib treatments of the lung cancer in an elderly patient result in gastrointestinal bleeding.厄洛替尼和吉非替尼治疗老年肺癌导致胃肠道出血。
Pak J Med Sci. 2013 Sep;29(5):1278-9. doi: 10.12669/pjms.295.3661.
10
Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature.吉非替尼治疗后非小细胞肺癌脑转移出血：两例病例报告及文献复习。
BMC Cancer. 2010 Feb 21;10:49. doi: 10.1186/1471-2407-10-49.
Zotero 插件